by 
Cell-based assays are now an essential part of drug discovery and development processes by the pharmaceutical and biotechnology industries. Cell-based assays are tests using live human, animal or bacterial cells to analyze cell metabolic responses when exposed to various substances and drug molecules. Cells are used to study the effects of new drug candidates, toxic chemicals or disease states, providing critical insights into how the tested substances will interact with live biological systems. The information from cell-based assays helps researchers improve drug safety and efficacy. The global Cell-based Assay Market is estimated to be valued at US$ 1389.05 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends driving growth in the cell-based assay market is the increasing R&D investments by pharmaceutical companies into developing novel therapeutics using advanced cell-based screening techniques. Miniaturization of assays and development of high-throughput screening technologies have enabled testing of thousands of compounds simultaneously, improving drug discovery efficiency. Growing preference for cell-based assays over animal models is another factor augmenting market revenue, as cell-based techniques provide human-relevant disease models while avoiding ethical issues associated with animal testing. Continuous technological advancements incorporating automation, high-content imaging, and assay multiplexing are also expanding the capabilities of cell-based assays.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the cell-based assay market is moderate. Establishing manufacturing facilities requires significant investment which deters new players. However, the growing market demand provides opportunities for new companies with innovative technologies.
Bargaining power of buyers: The bargaining power of buyers in the cell-based assay market is high. Buyers have a variety of options available from different manufacturers. This forces companies to efficiently cater to specific research needs and offer competitive prices.
Bargaining power of suppliers: The bargaining power of suppliers is moderate. While key materials required are specialist in nature, availability of alternative suppliers prevents over-dependence on any single vendor.
Threat of new substitutes: The threat of substitutes is low. While cell-free assays provide alternatives, cell-based approaches offer several advantages like examining cellular behavior. This reduces chances of technology disruptions.
Competitive rivalry: The competitive rivalry is high owing to presence of numerous global and regional players. Companies strive to stay ahead through extensive R&D in assay development, automation, and analytics solutions.
Key Takeaways
The global cell-based assay market is expected to witness high growth. Developing regions like Asia Pacific and Latin America are emerging as high potential markets due to increasing research intensity.
Regional analysis: North America currently dominates the market owing to well-established life science industry and major presence of global players. However, Asia Pacific is projected to witness fastest growth during the forecast period driven by rising biotech hubs in China, India, and other Asia Pacific countries.
Key players: Key players operating in the cell-based assay market are DiscoverX Corporation, Becton, Dickinson and Company, cell Signaling Technology, Inc., Becton, Danaher Corporation, Thermo Fisher Scientific, Inc., Cisbio Bioassays, Merck & Co., and PerkinElmer, Inc. and others. Companies are focusing on developing high-throughput screening platforms, assays for alternative models, and services to expand market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
